Literature DB >> 16339657

Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants?

Eliezer A Rachmilewitz1, Orly Weizer-Stern, Konstantin Adamsky, Ninette Amariglio, Gideon Rechavi, Laura Breda, Stefano Rivella, Z Ioav Cabantchik.   

Abstract

The pathophysiology of thalassemia is, to a certain extent, associated with the generation of labile iron in the pathological red blood cell (RBC). The appearance of such forms of iron at the inner and outer cell surfaces exposes the cell to conditions whereby the labile metal promotes the formation of reactive oxygen species (ROS) leading to cumulative cell damage. Another source of iron accumulation results from increased absorption due to decreased expression of hepcidin. The presence of labile plasma iron (LPI) was carried out using fluorescent probes in the FACS. RNA expression of hepcidin was measured in two models of thalassemic mice. Hepcidin expression was also measured in human hepatoma HepG2 cells following incubation with thalassemic sera. LPI was identified and could be quantitatively measured and correlated with other parameters of iron overload. Hepcidin expression was downregulated in the livers of thalassemic mice, in major more than in intermedia. Thalassemic sera down regulated hepcidin expression in HepG2 liver cells. A possible way to decrease iron absorption could be by modulating hepcidin expression pharmacologically, by gene therapy or by its administration. Treatment with combination of antioxidants such as N-acetylcysteine for proteins and vitamin E for lipids in addition to iron chelators could neutralize the deleterious effects of ROS and monitored by quantitation of LPI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339657     DOI: 10.1196/annals.1345.014

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

Review 1.  Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Authors:  Ellis J Neufeld
Journal:  Blood       Date:  2006-05-01       Impact factor: 22.113

2.  Suppression of hepcidin during anemia requires erythropoietic activity.

Authors:  Mihwa Pak; Miguel A Lopez; Victroia Gabayan; Tomas Ganz; Seth Rivera
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 3.  Cardiac complications in beta-thalassemia: From mice to men.

Authors:  Sirinart Kumfu; Suthat Fucharoen; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Exp Biol Med (Maywood)       Date:  2017-05-09

4.  Heterozygous beta-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C.

Authors:  Massimo Sartori; Silvano Andorno; Michela Pagliarulo; Cristina Rigamonti; Cristina Bozzola; Patrizia Pergolini; Roberta Rolla; Anna Suno; Renzo Boldorini; Giorgio Bellomo; Emanuele Albano
Journal:  Gut       Date:  2006-11-29       Impact factor: 23.059

Review 5.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

Review 6.  Ineffective erythropoiesis and thalassemias.

Authors:  Stefano Rivella
Journal:  Curr Opin Hematol       Date:  2009-05       Impact factor: 3.284

Review 7.  Cancer cells with irons in the fire.

Authors:  Laura M Bystrom; Stefano Rivella
Journal:  Free Radic Biol Med       Date:  2014-05-14       Impact factor: 7.376

8.  Low IL-2 Expressing T Cells in Thalassemia Major Patients: Is It Immune Aging.

Authors:  Batoul Pourgheysari; Leila Karimi; Raihaneh Bagheri; Soleiman Kheiri
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-07       Impact factor: 0.900

9.  Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.

Authors:  Gillian C Smith; Francisco Alpendurada; John Paul Carpenter; Mohammed H Alam; Vasili Berdoukas; Markissia Karagiorga; Vasili Ladis; Antonio Piga; Athanassios Aessopos; Efstathios D Gotsis; Mark A Tanner; Mark A Westwood; Renzo Galanello; Michael Roughton; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2011-07-06       Impact factor: 5.364

Review 10.  Oxidative stress in β-thalassaemia and sickle cell disease.

Authors:  S Voskou; M Aslan; P Fanis; M Phylactides; M Kleanthous
Journal:  Redox Biol       Date:  2015-08-01       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.